JP2024501471A5 - - Google Patents
Info
- Publication number
- JP2024501471A5 JP2024501471A5 JP2023535799A JP2023535799A JP2024501471A5 JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5 JP 2023535799 A JP2023535799 A JP 2023535799A JP 2023535799 A JP2023535799 A JP 2023535799A JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- approximately
- pharmaceutical composition
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125371P | 2020-12-14 | 2020-12-14 | |
| US63/125,371 | 2020-12-14 | ||
| PCT/US2021/063130 WO2022132652A1 (en) | 2020-12-14 | 2021-12-13 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501471A JP2024501471A (ja) | 2024-01-12 |
| JP2024501471A5 true JP2024501471A5 (cg-RX-API-DMAC7.html) | 2024-12-23 |
Family
ID=79288002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535799A Pending JP2024501471A (ja) | 2020-12-14 | 2021-12-13 | エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193072A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259137A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024501471A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230121801A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116744925A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021401580A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202592A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303143A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007058A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237117A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022132652A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN115746058A (zh) * | 2021-09-03 | 2023-03-07 | 南京知和医药科技有限公司 | 一种多环化合物在制备抗肿瘤药物方面的用途 |
| EP4554948A1 (en) * | 2022-07-12 | 2025-05-21 | Regents of the University of Michigan | Tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2024049926A1 (en) * | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
| WO2024196053A1 (ko) * | 2023-03-17 | 2024-09-26 | 재단법인 대구경북첨단의료산업진흥재단 | 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물 |
| TW202440096A (zh) * | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| JP2026518466A (ja) * | 2023-06-02 | 2026-06-08 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解剤とakt阻害剤との組み合わせ |
| JP2026519559A (ja) | 2023-06-02 | 2026-06-16 | ファイザー・インク | エストロゲン受容体分解薬およびcdk4阻害剤の組合せ |
| WO2025122502A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Methods for treating hr-positive her2-negative breast cancer |
| CN121646481A (zh) * | 2024-07-04 | 2026-03-10 | 海创药业股份有限公司 | 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途 |
| WO2026128391A1 (en) | 2024-12-09 | 2026-06-18 | Arvinas Operations, Inc. | Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SG11201607334YA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| MX384605B (es) * | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| MX2021006411A (es) * | 2018-12-06 | 2021-07-21 | Radius Pharmaceuticals Inc | Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6). |
| WO2021041348A1 (en) * | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
-
2021
- 2021-12-13 IL IL303143A patent/IL303143A/en unknown
- 2021-12-13 KR KR1020237023551A patent/KR20230121801A/ko active Pending
- 2021-12-13 US US17/548,842 patent/US20220193072A1/en active Pending
- 2021-12-13 EP EP21840327.7A patent/EP4259137A1/en active Pending
- 2021-12-13 CA CA3202592A patent/CA3202592A1/en active Pending
- 2021-12-13 WO PCT/US2021/063130 patent/WO2022132652A1/en not_active Ceased
- 2021-12-13 MX MX2023007058A patent/MX2023007058A/es unknown
- 2021-12-13 CN CN202180092119.4A patent/CN116744925A/zh active Pending
- 2021-12-13 AU AU2021401580A patent/AU2021401580A1/en active Pending
- 2021-12-13 TW TW110146570A patent/TW202237117A/zh unknown
- 2021-12-13 JP JP2023535799A patent/JP2024501471A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12280050B2 (en) | Therapeutic compositions, combinations, and methods of use | |
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| CN101677977A (zh) | 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合 | |
| JP2024533423A (ja) | 薬学的組成物およびその使用 | |
| EP2662082A1 (en) | Administration of mTOR inhibitors | |
| WO2023081830A2 (en) | Compositions and treatments with nirogacestat | |
| US20250186446A1 (en) | Organic compounds | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| TWI719765B (zh) | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 | |
| CN118678958A (zh) | 药物组合物及其用途 | |
| JP2025163103A (ja) | 放射線および/または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 | |
| TW201309298A (zh) | 治療惡性神經膠質瘤之醫藥組合物 | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| CN119894514A (zh) | 药物组合物及其用途 | |
| HK40130794A (en) | Vs-6063 in combination with ch5126766 for the treatment of cancer | |
| HK40116696A (en) | Pharmaceutical composition and use thereof | |
| HK40110967A (en) | Pharmaceutical composition and use thereof |